COMMUNIQUÉS West-GlobeNewswire

Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy
03/12/2018
Company changes name to Outlook Therapeutics, Inc.; ticker symbol to “OTLK” Jeff Evanson joins team as Chief Commercial Officer Terry Dagnon joins team as Chief Operating Officer Closed second tranche of private [...]
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
03/12/2018
Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo Clinically Meaningful [...]
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
03/12/2018
Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019 NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that it has completed patient [...]
Golden Leaf Holdings favorably restructures deal terms with Tahoe Hydroponics
03/12/2018
PORTLAND, Ore., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around [...]
Eve & Co Provides Update on Phase 2 Expansion
03/12/2018
TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (TSX-V: EVE) (“Eve & Co” or the “Company”) is pleased to provide an update on its 780,000 square foot greenhouse expansion. The construction of [...]
TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
03/12/2018
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, [...]
Press release: Terveystalo renews its management structure - decision making and service development closer to the customer
03/12/2018
The business environment in health care is experiencing great change. In order to ensure future competitiveness and to better respond to changing customer expectations and future challenges, Terveystalo will restructure [...]
Enochian Biosciences to Present at Biotech Showcase 2019
03/12/2018
LOS ANGELES, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) (OTCQB: ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell therapy platforms to [...]
Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer
03/12/2018
-Potential to Improve Early Detection and Transform the Treatment Landscape for Recurrent Prostate Cancer - NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company [...]
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
03/12/2018
Results demonstrate single intravitreal administration of ADVM-022 gene therapy may provide a safe and effective long-term treatment option for wet AMD, potentially decreasing the need for frequent anti-VEGF injections [...]
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
03/12/2018
REHOVOT, Israel and NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of [...]
Novo Nordisk A/S - Share repurchase programme
03/12/2018
Bagsværd, Denmark, 3 December 2018 - On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
XBiotech Announces Successful Completion of GMP Audit
03/12/2018
First Audit in Company’s New Manufacturing Facility Shows Compliance with GMP Guidelines AUSTIN, Texas, Dec. 03, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced a successful GMP (Good Manufacturing [...]
Data Presented at AACR Special Conference on PI3K/mTOR Signaling Demonstrates Potential of eFFECTOR’s eIF4E Inhibitors in Cancer
03/12/2018
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it presented [...]
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2019 After Market Close on December 10, 2018
03/12/2018
TUSTIN, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]
Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
03/12/2018
U.S. launch scheduled for early in the first quarter of 2019 Catalyst is well-capitalized and sees no current need for capital infusion CORAL GABLES, Fla., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc [...]
Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita®
03/12/2018
PLANO, Texas, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) head-only MR- [...]
Selecta Biosciences Announces New Employment Inducement Grants
03/12/2018
WATERTOWN, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
03/12/2018
Pre-NDA Meeting to be Requested for First Quarter of 2019 Company to Host Conference Call and Webcast Today, Monday, December 3, at 5:30 a.m. PT/8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE [...]

Pages